Informasjon

Tester og undersøkelser ved brystkreft

Brystkreft oppdages som regel gjennom rutineundersøkelser eller ved at du har selv oppdaget en kul eller forandringer i brystet som ble utredet videre.

Vil du vite mer?

Brystkreft, oversikt
Brystkreft, fakta
Brystkreft, årsaker
Brystkreft, varselstegn
Brystkreft, behandling
Arvelig brystkreft
Brystkreft, hvordan er det å leve med
Brystkreft - for helsepersonell
Ved behov for ytterligere råd eller veiledning, kontakt Brystkreftforeningen
Animasjon om egenundersøkelse av brystene
Mammografi

Vil du vite mer?

Få tilgang på artikkelen om dette temaet fra Legehandboka.no

Artikkelen inneholder all informasjon norske allmennleger bruker i sitt daglige arbeid.

Jeg har lest og akseptert Brukervilkår ved kjøp av NEL-dokumenter

Dette dokumentet er basert på det profesjonelle dokumentet "Brystkreft". Referanselisten for dette dokumentet vises nedenfor.

Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. Oslo: Helsedirektoratet; 2018. helsedirektoratet.no
Kreftregisteret. Cancer in Norway 2014. Oslo, 2014: kreftregisteret.no
Dødsårsaksregistert 2009. Oslo: Statistisk Sentralbyrå, 2011.
Kroman NT, Lidegaard Ø, Kvistgaard ME. Mammacancer - en livsstilssygdom?. Ugeskr Læger 2005; 167: 4636-41. PubMed
Hofvind S, Sørum R, Haldorsen T, Langmark F. Brystkreftforekomst før og etter innføring av mammografiscreening. Tidsskr Nor Lægeforen 2006; 126: 2935-8. PubMed
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-82. PubMed
Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. PMID: 29346467 PubMed
Møller P, Stormorken A, Holmen MM et al. The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation. Breast Cancer Res Treat 2014; 144: 607-14. pmid:24619173 PubMed
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol 2015; 26: 1291-99. pmid:25605744 PubMed
Pinkerton JAV, Aguirre FS, Blake J et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017 Jul 1;24(7):728-753. PMID: 28650869 PubMed
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data fra 47 epidemiological studies in 30 countries, including 50.302 women with breast cancer and 96.973 women without the disease. Lancet 2002; 20: 187-95. PubMed
Jernström H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004; 96: 1094-8. PubMed
Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Roth Hoff S, Lee CI: Mammographic Performance in a Population-based Screening Program: Before, during, and after the Transition from Screen-Film to Full-Field Digital Mammography. Radiology Jan 1. 2014. PMID: 24689858 PubMed
Chlebowski RT, Anderson GL, Gass, M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1864-92. PMID: 20959578 PubMed
Anderson GL, et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; : e-pub. PMID: 22401913 PubMed
Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011; 83: 211-7. PubMed
Luo J, Margolis KL, Wactawski-Wende J, et al. Association of active and passive smoking with breast cancer among postmenopausal women: a prospective cohort study. BMJ 2011; 342. PMID: 21363864 PubMed
Ahern TP, Broe A, Lash TL et al. Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study. J Clin Oncol 2019; 17: 1802202. pmid:30995175 PubMed
Neuhouser ML, Aragaki AK, Prentice RL, et al. Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015 Aug;1(5):611-21. PMID: 26182172 PubMed
Travis RC, Balkwill A, Fensom GK, et al. Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies. JNCI J Natl Cancer Inst 2016; 108 (12): djw169. PMID: 27758828 PubMed
International Agency for Research on Cancer. Volume 124: Night shift work. IARC Working Group. Lyon, France; June 4–11, 2019. IARC Monogr Eval Carcinog Risk Chem Hum (in press)
Siu AL; U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2016; 164: 279-96. pmid:26757170 PubMed
Warner E, Messersmith H, Causer P, et al. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148: 671-9.
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-86. pmid:23117178 PubMed
Research-based evaluation of the Norwegian Breast Cancer Screening Program. Oslo: Norsk forskningsråd. Divisjon for samfunn og helse. ; mai 2015. www.forskningsradet.no
Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA. 2014 Apr 2;311(13):1327-35. PMID: 24691608. PubMed
Hofvind S, Geller BM, Skelly J, Vacek PM. Sensitivity and specificity of mammographic screening as practised in Vermont and Norway. Br J Radiol 2012; 85: e1226-32. pmid:22993383 PubMed
Nasjonalt kunnskapssenter for helsetjenesten. Mammography screening of women 40–49. Rapport nr. 09 – 2007. Changed 2014. www.kunnskapssenteret.no
Nelson HD, Pappas M, Cantor A, et al. Harms of breast cancer screening: Systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Jan 12. PMID: 26756737 PubMed
Myers ER, Moorman P, Gierisch JM et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA. 2015 Oct 20;314(15):1615-34. PubMed
Kalager M, Zelen M, Langmark F, Adami H-O. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203-10. PMID: 20860502 PubMed
Tabár L, Vitak B, Chen TH-H, et al. Swedish two-county trial: Impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260(3):658-63. PMID: 21712474 PubMed
Birnbaum J., Gadi VK., Markowitz E. et al. The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Ann Intern Med 2016; 164: 236-43. pmid:26756332 PubMed
Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2013, Issue 6. CD001877.pub5 Cochrane (DOI)
Hofvind S, Thorsen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer 2004; 101: 1501-07. pmid:15378474 PubMed
Kalager M1, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-9. pmid:22473436 PubMed
Lund E., Nakamura A., Thalabard JC. No overdiagnosis in the Norwegian Breast Cancer Screening Program estimated by combining record linkage and questionnaire information in the Norwegian Women and Cancer study. Eur J Cancer 2017; 89: 102-12. pmid:29245077 PubMed
Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587. PMID: 19589821 PubMed
Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med 2017; 166: 313-23. pmid:28114661 PubMed
Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database of Systematic Reviews 2013, Issue 11. CD000563.pub7 Cochrane (DOI)
Lee LA, Silverstein MJ, Chung CT, et al. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg 2006; 192: 416-9. PubMed
Hartmann-Johnsen OJ, Kåresen R, Schlichting E, Nygård JF. Survival is Better After Breast Conserving Therapy than Mastectomy for Early Stage Breast Cancer: A Registry-Based Follow-up Study of Norwegian Women Primary Operated Between 1998 and 2008. Ann Surg Oncol 2015. PMID:25743325 PubMed
Jeevan R, Cromwell DA, Trivella M, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ 2012; 345. PMID: 22791786 PubMed
Curigliano G, Burstein HJ, P Winer E et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28: 1700-12. pmid:28838210 PubMed
Goss PE, Ingle JN, Pritchard KI et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209-19. pmid:27264120 PubMed
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717. pmid:15894097 PubMed
Early breast cancer trialists' group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials . Lancet Oncol 2015. PMID: 26211824 PubMed
Kümler I, Knoop AS, Jessing CA. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. 2016 Aug 16;1(4):e000062. pmid: 27843622 PubMed
Ghersi D, Willson ML, Chan M, Simes J, Donoghue E, Wilcken N. Taxane-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD003366. DOI: 10.1002/14651858.CD003366.pub3 DOI
Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N. Platinum-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD003374. DOI: 10.1002/14651858.CD003374.pub4 DOI
O'Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD003474. DOI: 10.1002/14651858.CD003474.pub4 DOI
Himelstein AL, Foster JC, Khatcheressian JL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial. JAMA 2017; 317(1): 48-58. pmid:28030702 PubMed
Helsedirektoratet. Seneffekter etter kreftbehandling. Faglige råd. Oslo: Helsedirektoratet; 2017. IS-2551 helsedirektoratet.no
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98. PMID: 23484825 PubMed
Torres Lacomba M, Yuste Sánchez MJ, Zapico Goñi Á et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ 2010; 340: b5396. PMID: 20068255 PubMed
Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med 2009; 361: 664-73. PMID: 19675330 PubMed
Segal R, Evans W, Johnson D, Smith J, et al. Structured exercise improves physical functioning in women with stages I and II breast cancer: Results of a randomized controlled trial. Journal of Clinical Oncology 2001; 19: 657-65. PubMed
McNeely ML, Campbell K, Ospina M, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database of Systematic Reviews 2010, Issue 6. CD005211.pub2. Cochrane (DOI)
Fahlen M, Fornander T, Johansson H et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. European journal of cancer. 2013;49(1):52-9. PMID: 22892060 PubMed
Bak AM, Laursen BE, Rungby J, Brock B. Vaginal østrogenbehandling ved hormonfølsom brystkræft. Ugeskr Læger 2011; 173: 648. ugeskriftet.dk
Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD004923. DOI: 10.1002/14651858.CD004923.pub2 DOI
Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818-24. PubMed
Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693. PMID: 20142325 PubMed
Turner NC, Jones AL. Management of breast cancer. Clinical Review. BMJ 2008; 337: 107-10. PubMed
Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database of Systematic Reviews 2003, Issue 2. CD003373 Cochrane (DOI)
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology 2014. PMID: 25497694 PubMed
Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27: 3235-58. PubMed
Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American society of clinical oncology clinical practice guideline. J Clin Oncol 2013. pmid:23835710 PubMed
Cuzick J, Sestak I, Forbes JF, et al. Anastrazole for prevention of brast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2013. PMID: 24333009 PubMed
Holmes MD, Chen WY, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28: 1467-72. PubMed
Armstrong AC, Evans GD. Management of women at high risk of breast cancer. Clinical review. BMJ 2014; 348: g2756. PMID: 24778341 PubMed
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 og BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304: 967-75. PMID: 20810374 PubMed
Veileder gynekologisk onkologi. Norsk gynekologisk forening 2016. legeforeningen.no
Portschy PR, Kuntz KM, Tuttle TM. Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. J Natl Cancer Inst 2014. PMID: 25031308 PubMed
DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lacet Oncol 2013; 14: 500-15. PubMed
Kuchenbaecker KB, Hopper JL, Barnes DR et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317: 2402-16. pmid:28632866 PubMed
Chan DS, Norat T. Obesity and breast cancer: not only a risk factor of the disease. Curr Treat Options Oncol. 2015 May;16(5):22. PMID:25904412 PubMed
Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews 2016, Issue 5. CD001768.pub3 Cochrane (DOI)
The American College of Obstetricians ang Gynecologists. Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol 2014; 123: 1394-7. pmid:24848920 PubMed
Møller P, Mæhle L, Apold J. Arvelig brystkreft. Tidsskr Nor Lægeforen 2005; 125: 3136-8. PubMed
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-92. PMID: 16251534 PubMed
Early Breast Cancer Trialist's Collaboratory Group (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 366: 2087-2106. PubMed
Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 2017; 375: 1438-47. pmid:27732805 PubMed
Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014;311(24):2499-2507. PMID: 25058084 PubMed

Meld deg på nyhetsbrev

Er du helsepersonell?

Ved å oppgi dette kan du få bedre tilpasset innhold om du har formell helsefaglig kompetanse

Annonsørinnhold

Annonsørinnhold fra Amgen

Kjenn ditt kolesterol!

I videoen «Kjenn ditt kolesterol» møter vi 50 år gamle Lise som under en sykkeltur får et hjerteinfarkt. Videoen forklarer sammenhengen mellom høyt kolesterol og hjerteinfarkt. Kjenner du ditt kolesterol?

Annonsørinnhold fra SanaPharma

Behandling av søvnproblemer

Mange har vanskelig for å falle til ro for å sovne om kvelden. Andre sliter med å sove godt igjennom natten. Slik kan du få reseptfri hjelp.

Mest lest i dag

Blod

Mangel på vitamin B12

Mangel på vitamin B12 skyldes utilstrekkelig inntak via kostholdet eller redusert opptak av vitamin B12 fra tarmen. Tilstanden kan være vanskelig å oppdage tidlig, fordi symptomene kan være vage og utvikles langsomt. Diagnosen stilles ved en blodprøve.

Barn

Omgangssyke, tarminfeksjon

Virusinfeksjon i tarmen, omgangssyke, er en vanlig årsak til kortvarig diarè og oppkast.

Hud

Skabb

Skabb er en hudsykdom som skyldes en skabbmidd som graver ganger i huden og legger egg. Typiske symptomer er plutselig plagsom kløe, som oppleves mest intens om natten.

Tester og undersøkelser ved brystkreft

Hopp til innhold

Vil du vite mer?

Er du helsepersonell?

Andre leste også dette

Annonsørinnhold

Mest lest i dag